Range of eligible people: CDEC discussed the uncertainty in the quantity of people with moderately significant to severe hemophilia B in Canada suitable for etranacogene dezaparvovec. Clinical professionals consulted by CADTH indicated that some sufferers who are classified as acquiring gentle or moderate sickness may have a critical bleeding pheno